License and Sublicense Agreement Sample Contracts
LICENSE AND SUBLlCENSE AGREEMENTLicense and Sublicense Agreement • November 10th, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances) • Delaware
This License and Sublicense Agreement (“Agreement”) is made effective as of May 22, 2017 (“Effective Date”) by and between on the one hand On Target Therapeutics, LLC, 1S Wynnewood Road, Wellesley, MA 02481 (“On Target” or ‘‘Licensor’’), and Biovitas Capital, 18 South Street, Mayfair, London, W1K 1DG, UK (“Licensee”). Licensor and Licensee are each hereafter referred to individually as a “Party” and together as the “Parties.”
LICENSE AND SUBLICENSE AGREEMENT BETWEEN LYOTROPIC THERAPEUTICS, INC. AND EAGLE PHARMACEUTICALS, INC.License and Sublicense Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is made and entered into this 16th day of October, 2008 (the “Effective Date”), between Lyotropic Therapeutics, Inc., a Virginia corporation (“Lyotropic”), and Eagle Pharmaceuticals, Inc., a Delaware corporation (“Eagle”).
FIRST AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT BY AND BETWEEN ON TARGET THERAPEUTICS LLC AND OKYO PHARMA LIMITEDLicense and Sublicense Agreement • March 4th, 2022 • OKYO Pharma LTD • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT (“First Amendment”) is dated as of March 25, 2021 (the “First Amendment Effective Date”) by and between On Target Therapeutics, LLC, 15 Wynnewood Road, Wellesley, MA 02481 and (“On Target”) and OKYO Pharma Limited, Martello Court, Admiral Park, St. Peter Port, Guernsey, GY1 3HB (“OKYO”).
AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT BY AND BETWEEN CPEC LLC AND ARCA DISCOVERY INC.License and Sublicense Agreement • May 15th, 2009 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
THIS AMENDMENT (the “Amendment”), dated as of February, 22, 2006 (“Amendment Effective Date”), by and between CPEC LLC, a Delaware limited liability company having an office at 33 Hayden Avenue, Lexington, MA 02421 (“CPEC”) and ARCA Discovery, Inc., a corporation organized and existing under the laws of the State of Colorado and having its principal office at 1400 Sixteenth Street, Suite 220, Denver, Colorado 80202 (“ARCA”), amends the License and Sublicense Agreement effective as of October 28, 2003 (the “License Agreement”) by and between CPEC and ARCA.
FERRING INTERNATIONAL CENTER SA and I-MAB LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations
THIS LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is effective as of 4th of November 2016 (the “Effective Date”), and is by and between FERRING INTERNATIONAL CENTER SA, a company organised and existing under the laws of Switzerland and having its principal place of business at Chemin de la Vergognausaz 50 CH-1162 Saint-Prex Switzerland (“Ferring”) and I-MAB, a company organised and existing under the laws of Cayman Islands and having its principal place of business at Floor 4, Willow House, Cricket Square, P 0 Box 2804, Grand Cayman KY1-1112, Cayman Islands, (“I-MAB”). Each party individually may be referred to herein as a “Party” and collectively both parties may be referred to herein as the “Parties.”
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • England
This License AND Sub-License Agreement (“Agreement”), effective as of March 19, 2018 (the “Effective Date”), is made by and between LipocureRX, Ltd., a company organized and existing under the laws of Israel (“Lipocure”), and Virpax Pharmaceuticals, Inc., a Delaware corporation (“Virpax”).
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • May 9th, 2013 • Coronado Biosciences Inc • Pharmaceutical preparations
This License and Sublicense Agreement (“Agreement”) is entered into by and between the Parties as of the Effective Date (as defined herein).
AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT BY AND BETWEEN CPEC LLC AND ARCA DISCOVERY INC.License and Sublicense Agreement • November 6th, 2009 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Colorado
THIS INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 22nd day of February, 2006, by and among ARCA Discovery, Inc. a Delaware corporation (the “Company”), the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
Confidential Treatment Requested by American Superconductor CorporationLicense and Sublicense Agreement • May 31st, 2016 • American Superconductor Corp /De/ • Motors & generators
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • May 31st, 2016 • American Superconductor Corp /De/ • Motors & generators • New York
THIS LICENSE AND SUBLICENSE AGREEMENT (this “License”) is made effective as of March 4, 2016 (subject to the provisions of this License, the “Effective Date”) by and between AMERICAN SUPERCONDUCTOR CORPORATION, a Delaware corporation having an office and place of business at 64 Jackson Road, Devens, MA 01434 (“AMSC”), and BASF CORPORATION, a Delaware corporation having a place of business at 100 Park Avenue, Florham Park, NJ 07932 (“BASF”). AMSC and BASF are each hereinafter referred to individually as a “Party” and together as the “Parties.”
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • February 22nd, 2024 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • California
This License and Sublicense Agreement (this “Agreement”) is entered into as of February 15, 2024 (the “Effective Date”) by Qualigen Therapeutics, Inc., a Delaware corporation (“QLGN”), on the one hand, and Pan-RAS Holdings, Inc., a New York corporation (“Pan-RAS”), on the other hand.
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • March 16th, 2006 • Gene Logic Inc • In vitro & in vivo diagnostic substances • California
THIS LICENSE AND SUBLICENSE AGREEMENT (“AGREEMENT”) is made this 12th day of September, 2005 by and between PROMEGA CORPORATION, a corporation organized and existing under the laws of the State of Wisconsin and with principal offices located at 2800 Woods Hollow Road, Madison, Wisconsin, 53711 ("LICENSOR") and Gene Logic Inc., a corporation organized and existing under the laws of the State of Delaware with principal offices located at 610 Professional Drive, Gaithersburg, MD 20879 (“LICENSEE”) (each a “Party”, and together the “Parties” herein).